Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers
Arch Gynecol Obstet
.
2017 Feb;295(2):269-271.
doi: 10.1007/s00404-016-4262-z.
Epub 2016 Dec 10.
Authors
Patrick Carlier
1
,
Maritza Markarian
,
Nathalie Bernard
2
,
Laurence Lagarce
3
,
Anne Dautriche
4
,
Johana Béné
5
,
Nathalie Fouilhé Sam-Lai
6
,
Pirayeh Eftekhari
7
Affiliations
1
Centre régional de Pharmacovigilance, Hôpital Fernand-Widal,AP-HP, Paris, France. pharmacovigilance.fwd.lrb@aphp.fr.
2
Centre régional de Pharmacovigilance, Hospices Civils de Lyon, Lyon, France.
3
Centre régional de Pharmacovigilance, CHRU Angers, Angers, France.
4
Centre régional de Pharmacovigilance, CHU Dijon, Dijon, France.
5
Centre régional de Pharmacovigilance du Nord Pas de Calais, CHU Lille, 59000, Lille, France.
6
Centre régional de Pharmacovigilance, CHU Grenoble Alpes, Grenoble, France.
7
Centre régional de Pharmacovigilance, Hôpital Fernand-Widal,AP-HP, Paris, France.
PMID:
27942835
DOI:
10.1007/s00404-016-4262-z
No abstract available
Publication types
Letter